Revisiting the 1976 "Swine Flu" Vaccine Clinical Trials: Cross-reactive Hemagglutinin and Neuraminidase Antibodies and Their Role in Protection Against the 2009 H1N1 Pandemic Virus in Mice
Open Access
- 5 October 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (12), 1179-1187
- https://doi.org/10.1093/cid/cir693
Abstract
Background. The 2009 H1N1 pandemic viruses are genetically similar to A/New Jersey/76 H1N1 virus (NJ/76), the strain selected for the 1976 “swine flu” vaccines. Approximately 45 million people in the United States were vaccinated against NJ/76 30 years ago, but the impact of this nationwide immunization on the current pandemic is largely unknown. Methods. Archived human serum samples collected during the 1976 swine flu vaccine trials were assessed for cross-reactive antibody responses to the 2009 H1N1 pandemic viruses. Results. Administration of an NJ/76 monovalent vaccine or the combination of a bivalent vaccine (NJ/76 H1N1 and A/Victoria/75 H3N2) plus a B/Hong Kong/72 monovalent vaccine increased hemagglutinin inhibition (HAI) and neuraminidase inhibition (NAI) antibodies cross-reacting with the 2009 H1N1 pandemic viruses. We showed that cross-reactive human HAI antibodies elicited by the 1976 swine flu vaccination played a dominant role in protecting recipient mice against the wild-type A/California/04/2009. Cross-reactive human NAI antibodies were also protective in recipient mice after a lethal challenge with a hemagglutinin mismatched virus bearing the A/California/04/2009 neuraminidase gene. Transfer of human serum samples with an original HAI titer of 43 or an original NAI titer of 472 was estimated to protect 50% of recipient mice from a lethal infection under the experimental conditions described. Conclusions. The 1976 swine flu vaccination induced cross-reactive HAI and NAI antibodies that were functionally protective in mice, suggesting that this vaccination campaign might have had a positive impact on older adults (≥50 years) in the United States during the 2009 H1N1 pandemic.Keywords
This publication has 25 references indexed in Scilit:
- Immunogenicity and Cross-Reactivity of 2009–2010 Inactivated Seasonal Influenza Vaccine in US Adults and ElderlyPLOS ONE, 2011
- Inactivated Seasonal Influenza Vaccines Increase Serum Antibodies to the Neuraminidase of Pandemic Influenza A(H1N1) 2009 Virus in an Age‐Dependent MannerThe Journal of Infectious Diseases, 2010
- Reflections on Pandemic (H1N1) 2009 and the International ResponsePLoS Medicine, 2010
- Influenza Hemagglutinin and Neuraminidase Membrane GlycoproteinsJournal of Biological Chemistry, 2010
- Recipients of Vaccine against the 1976 “Swine Flu” Have Enhanced Neutralization Responses to the 2009 Novel H1N1 Influenza VirusClinical Infectious Diseases, 2010
- A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjectsVaccine, 2010
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusThe New England Journal of Medicine, 2009
- A miniaturized assay for influenza neuraminidase‐inhibiting antibodies utilizing reverse genetics‐derived antigensInfluenza and Other Respiratory Viruses, 2009
- Cross-Reactive Neuraminidase Antibodies Afford Partial Protection against H5N1 in Mice and Are Present in Unexposed HumansPLoS Medicine, 2007
- A DNA transfection system for generation of influenza A virus from eight plasmidsProceedings of the National Academy of Sciences of the United States of America, 2000